Artemisine-brand ACTs, artesunate & artemether — with documentation packages for WHO prequalification submissions and international malaria tenders.
Malaria still claims over 600,000 lives every year, most of them children under five in sub-Saharan Africa. Artemisine — the brand our company is named after — is our flagship antimalarial line: a complete, WHO-guideline-aligned portfolio from first-line artemisinin-based combination therapies (ACTs) to life-saving injectables for severe malaria.
Our ACT range covers the combinations recommended by the WHO Guidelines for Malaria: artemether-lumefantrine tablets (the world's most used ACT), artesunate-amodiaquine, dihydroartemisinin-piperaquine and artesunate-pyronaridine. For severe and complicated malaria we manufacture artesunate powder for injection, artemether injection and quinine dihydrochloride injection — the referral-level products WHO lists as essential.
For buyers preparing WHO prequalification (WHO PQ) submissions or bidding in international malaria tenders (Global Fund, PMI, national MOH programs), we supply complete documentation packages: CTD-format dossiers, batch COAs, COPP, stability data and GMP evidence from our 2026-re-inspected site. Pediatric malaria is covered by artemether and artesunate oral suspensions and artesunate suppositories for children who cannot swallow tablets.
All products are GMP manufactured and supplied with COA, COPP, DMF and CTD dossiers. Tap any product for specifications and WHO prescribing guidance.
Tell us your target market and annual volume — our export team replies within 24 hours.
Artemether-lumefantrine tablets, artesunate-amodiaquine, dihydroartemisinin-piperaquine, artesunate-pyronaridine, sulfadoxine-pyrimethamine combinations, artesunate powder for injection, artemether injection, quinine injection, chloroquine tablets, plus pediatric oral suspensions and artesunate suppositories.
Yes. The portfolio is manufactured to WHO-guideline-aligned specifications, and we prepare CTD-format dossiers, stability data and GMP documentation packages specifically structured to support WHO prequalification (PQ) submissions and stringent-authority registrations.
Yes. We support Global Fund, PMI and national ministry-of-health tender supply with batch COA, COPP, DMF/CTD dossiers, legalisation documents and tender-specific packaging/labeling.
Artemether oral suspension (15 mg/5 mL), artesunate oral suspension (10 mg/5 mL) and artesunate suppositories 100 mg — designed for infants and children with uncomplicated or severe malaria who cannot take tablets.
Artemisine Medicines